Tiziana Life Sciences (US) (TLSA) has released an update.
Tiziana Life Sciences has presented promising data at the American Academy of Neurology’s Annual Meeting, showing that its drug foralumab significantly reduces microglial activation and stabilizes disease progression in patients with secondary progressive multiple sclerosis (na-SPMS). The study revealed that intranasal foralumab treatment led to a reduction in neuroinflammation and maintenance of patient fatigue and disability scores over a period of 3 to 6 months. These findings support the ongoing placebo-controlled study of nasal foralumab as a potential early intervention treatment for na-SPMS.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
